Literature DB >> 16336966

Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.

J Miklossy1, D D Doudet, C Schwab, S Yu, E G McGeer, P L McGeer.   

Abstract

It has been established that neuroinflammation is present in the substantia nigra (SN) of Parkinson disease (PD) cases but the factors responsible are as yet unknown. One contributing protein may be the intercellular adhesion molecule-1 (ICAM-1, CD54). ICAM-1 with its counter receptor, the lymphocyte function-associated antigen 1 (LFA-1) is known to play a key role in inflammatory processes and in T-cell mediated host defense mechanisms. We detected large numbers of ICAM-1-positive reactive astrocytes in the SN of a series of 14 patients with neuropathologically confirmed PD, including 3 of familial origin, compared with 11 age-matched controls. In PD SN, these ICAM-1-positive reactive astrocytes were particularly concentrated around many residual neurons in areas of heavy neuronal loss and extracellular melanin accumulation. LFA-1-positive reactive microglia gathered in areas of intense ICAM-1 expression, and LFA-1-positive leukocytes were identified infiltrating the tissue. Double immunostaining for ICAM-1 and LFA-1 revealed aggregates of reactive microglia embedded in areas of diffuse ICAM-1. Leukocyte counts were 5 fold higher in PD SN compared to controls (P < 0.001). Similar over-expression of ICAM-1 was found in monkeys that had been exposed to MPTP from 5.5 to 14 years previously compared with control monkeys. The presence of ICAM-1-positive reactive astrocytes in Parkinson disease and MPTP-treated monkeys is indicative of a sustained inflammatory process and suggests that antiinflammatory agents may have a place in PD therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336966     DOI: 10.1016/j.expneurol.2005.10.034

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  76 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 2.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 3.  Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.

Authors:  Elisabetta Vegeto; Valeria Benedusi; Adriana Maggi
Journal:  Front Neuroendocrinol       Date:  2008-04-29       Impact factor: 8.606

4.  Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.

Authors:  Alexandra Isabel Rosa; Sara Duarte-Silva; Anabela Silva-Fernandes; Maria João Nunes; Andreia Neves Carvalho; Elsa Rodrigues; Maria João Gama; Cecília Maria Pereira Rodrigues; Patrícia Maciel; Margarida Castro-Caldas
Journal:  Mol Neurobiol       Date:  2018-04-12       Impact factor: 5.590

5.  Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.

Authors:  Junchao Tong; Lee-Cyn Ang; Belinda Williams; Yoshiaki Furukawa; Paul Fitzmaurice; Mark Guttman; Isabelle Boileau; Oleh Hornykiewicz; Stephen J Kish
Journal:  Neurobiol Dis       Date:  2015-06-21       Impact factor: 5.996

Review 6.  Immune system responses in Parkinson's disease: Early and dynamic.

Authors:  Malú G Tansey; Marina Romero-Ramos
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

Review 7.  Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.

Authors:  Li Qian; Patrick M Flood; Jau-Shyong Hong
Journal:  J Neural Transm (Vienna)       Date:  2010-06-23       Impact factor: 3.575

8.  Paroxetine suppresses reactive microglia-mediated but not lipopolysaccharide-induced inflammatory responses in primary astrocytes.

Authors:  Xiong Zhang; Lan-Bing Zhu; Jia-Hui He; Hong-Qiu Zhang; Shu-Ya Ji; Chao-Nan Zhang; Na-Na Hou; Chen-Ping Huang; Jian-Hong Zhu
Journal:  J Neuroinflammation       Date:  2020-02-05       Impact factor: 8.322

9.  Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes.

Authors:  Matthew Neal; Jie Luo; Dilshan S Harischandra; Richard Gordon; Souvarish Sarkar; Huajun Jin; Vellareddy Anantharam; Laurent Désaubry; Anumantha Kanthasamy; Arthi Kanthasamy
Journal:  Glia       Date:  2018-09-12       Impact factor: 7.452

10.  Carnosine exerts neuroprotective effect against 6-hydroxydopamine toxicity in hemiparkinsonian rat.

Authors:  Siamak Afshin-Majd; Mohsen Khalili; Mehrdad Roghani; Narges Mehranmehr; Tourandokht Baluchnejadmojarad
Journal:  Mol Neurobiol       Date:  2014-06-18       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.